ZA202209962B - Degradation of bruton’s tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use - Google Patents
Degradation of bruton’s tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of useInfo
- Publication number
- ZA202209962B ZA202209962B ZA2022/09962A ZA202209962A ZA202209962B ZA 202209962 B ZA202209962 B ZA 202209962B ZA 2022/09962 A ZA2022/09962 A ZA 2022/09962A ZA 202209962 A ZA202209962 A ZA 202209962A ZA 202209962 B ZA202209962 B ZA 202209962B
- Authority
- ZA
- South Africa
- Prior art keywords
- btk
- inidbitors
- bruton
- conjugation
- degradation
- Prior art date
Links
- 102000001714 Agammaglobulinaemia Tyrosine Kinase Human genes 0.000 title 1
- 108010029445 Agammaglobulinaemia Tyrosine Kinase Proteins 0.000 title 1
- 102000003960 Ligases Human genes 0.000 title 1
- 108090000364 Ligases Proteins 0.000 title 1
- 230000015556 catabolic process Effects 0.000 title 1
- 230000021615 conjugation Effects 0.000 title 1
- 238000006731 degradation reaction Methods 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020088322 | 2020-04-30 | ||
| CN2021085369 | 2021-04-02 | ||
| PCT/CN2021/090898 WO2021219070A1 (en) | 2020-04-30 | 2021-04-29 | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202209962B true ZA202209962B (en) | 2023-05-31 |
Family
ID=78374077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2022/09962A ZA202209962B (en) | 2020-04-30 | 2022-09-07 | Degradation of bruton’s tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230167118A1 (https=) |
| EP (1) | EP4146655A4 (https=) |
| JP (2) | JP7681038B2 (https=) |
| KR (1) | KR20230003161A (https=) |
| CN (4) | CN116589466B (https=) |
| AU (1) | AU2021264916A1 (https=) |
| BR (1) | BR112022019014A2 (https=) |
| CA (1) | CA3172498A1 (https=) |
| IL (1) | IL297664A (https=) |
| MX (1) | MX2022013407A (https=) |
| TW (1) | TWI902789B (https=) |
| WO (1) | WO2021219070A1 (https=) |
| ZA (1) | ZA202209962B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116589466B (zh) * | 2020-04-30 | 2025-08-15 | 百济神州有限公司 | 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法 |
| CN116981675A (zh) * | 2020-12-31 | 2023-10-31 | 百济神州有限公司 | 通过布鲁顿氏酪氨酸激酶（btk）抑制剂与e3连接酶配体的缀合降解btk和使用方法 |
| AU2022270089A1 (en) * | 2021-05-03 | 2023-11-16 | Nurix Therapeutics, Inc. | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use |
| TW202309039A (zh) * | 2021-05-05 | 2023-03-01 | 美商百健Ｍａ公司 | 用於靶向布魯頓氏酪胺酸激酶降解之化合物 |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| JP2024525181A (ja) * | 2021-06-21 | 2024-07-10 | ベイジーン スウィッツァーランド ゲーエムベーハー | （ｒ）－グルタルイミドｃｒｂｎリガンド及び使用方法 |
| KR20240128831A (ko) | 2021-12-30 | 2024-08-27 | 베이진 스위찰랜드 게엠베하 | 브루톤 티로신 키나아제(btk) 억제제와 e3 리가아제 리간드의 접합에 의한 btk의 분해 및 사용 방법 |
| WO2023125907A1 (en) * | 2021-12-30 | 2023-07-06 | Beigene, Ltd. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| JP7805983B2 (ja) | 2022-03-22 | 2026-01-26 | アッヴィ・インコーポレイテッド | ブルトン型チロシンキナーゼを分解するためのピリミジン |
| WO2024169871A1 (zh) * | 2023-02-17 | 2024-08-22 | 江苏威凯尔医药科技有限公司 | Btk抑制剂及其用途 |
| CN118946561A (zh) * | 2023-03-10 | 2024-11-12 | 标新生物医药科技(上海)有限公司 | 新颖的e3泛素连接酶配体、蛋白降解剂及其应用 |
| CN117126133A (zh) * | 2023-08-14 | 2023-11-28 | 中国海洋大学 | 一种化合物及其用途 |
| TW202532078A (zh) * | 2024-02-09 | 2025-08-16 | 瑞士商百濟神州瑞士有限責任公司 | 用嵌合降解活化化合物治療b細胞增殖性病症 |
| CN120623148A (zh) * | 2024-03-11 | 2025-09-12 | 北京深势科技有限公司 | 一种c-Myc降解剂及其制备方法和用途 |
| WO2025218772A1 (en) * | 2024-04-19 | 2025-10-23 | Beigene (Suzhou) Co., Ltd. | Solid forms comprising a bruton's tyrosine kinase degrader and uses therefor |
| WO2025232885A1 (en) * | 2024-05-10 | 2025-11-13 | Beigene (Suzhou) Co., Ltd. | Preparation method of a bruton's tyrosine kinase degrader thereof |
| WO2026012424A1 (zh) * | 2024-07-10 | 2026-01-15 | 江苏恒瑞医药股份有限公司 | 一种杂芳基类化合物、其制备方法及其在医药上的应用 |
| CN121405700A (zh) * | 2024-07-26 | 2026-01-27 | 苏州亚盛药业有限公司 | Btk降解剂及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013157021A1 (en) * | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| KR20150060839A (ko) * | 2012-10-26 | 2015-06-03 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
| EP3444251B1 (en) * | 2013-12-11 | 2023-06-07 | Biogen MA Inc. | Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology |
| CN111936498B (zh) * | 2018-03-26 | 2024-04-16 | 诺华股份有限公司 | N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物 |
| EP3774808A1 (en) * | 2018-03-26 | 2021-02-17 | Novartis AG | 3-hydroxy-n-(3-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)pyrrolidine-1-carboxamide derivatives |
| CN116589466B (zh) * | 2020-04-30 | 2025-08-15 | 百济神州有限公司 | 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法 |
-
2021
- 2021-04-29 CN CN202310380645.1A patent/CN116589466B/zh active Active
- 2021-04-29 EP EP21797070.6A patent/EP4146655A4/en active Pending
- 2021-04-29 IL IL297664A patent/IL297664A/en unknown
- 2021-04-29 TW TW110115475A patent/TWI902789B/zh active
- 2021-04-29 MX MX2022013407A patent/MX2022013407A/es unknown
- 2021-04-29 BR BR112022019014A patent/BR112022019014A2/pt unknown
- 2021-04-29 CN CN202180031447.3A patent/CN115485278A/zh active Pending
- 2021-04-29 WO PCT/CN2021/090898 patent/WO2021219070A1/en not_active Ceased
- 2021-04-29 CN CN202310380649.XA patent/CN116589467A/zh active Pending
- 2021-04-29 JP JP2022554565A patent/JP7681038B2/ja active Active
- 2021-04-29 KR KR1020227041734A patent/KR20230003161A/ko active Pending
- 2021-04-29 CN CN202511130551.4A patent/CN121159541A/zh active Pending
- 2021-04-29 CA CA3172498A patent/CA3172498A1/en active Pending
- 2021-04-29 US US17/919,847 patent/US20230167118A1/en active Pending
- 2021-04-29 AU AU2021264916A patent/AU2021264916A1/en active Pending
-
2022
- 2022-09-07 ZA ZA2022/09962A patent/ZA202209962B/en unknown
-
2025
- 2025-05-09 JP JP2025078734A patent/JP2025122005A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL297664A (en) | 2022-12-01 |
| CA3172498A1 (en) | 2021-11-04 |
| CN115485278A (zh) | 2022-12-16 |
| TWI902789B (zh) | 2025-11-01 |
| JP2023523130A (ja) | 2023-06-02 |
| MX2022013407A (es) | 2022-11-14 |
| EP4146655A1 (en) | 2023-03-15 |
| BR112022019014A2 (pt) | 2022-11-29 |
| EP4146655A4 (en) | 2024-07-31 |
| JP7681038B2 (ja) | 2025-05-21 |
| JP2025122005A (ja) | 2025-08-20 |
| CN121159541A (zh) | 2025-12-19 |
| TW202142542A (zh) | 2021-11-16 |
| WO2021219070A1 (en) | 2021-11-04 |
| CN116589467A (zh) | 2023-08-15 |
| CN116589466A (zh) | 2023-08-15 |
| AU2021264916A1 (en) | 2022-11-03 |
| CN116589466B (zh) | 2025-08-15 |
| US20230167118A1 (en) | 2023-06-01 |
| KR20230003161A (ko) | 2023-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202209962B (en) | Degradation of bruton’s tyrosine kinase (btk) by conjugation of btk inidbitors with e3 ligase ligand and methods of use | |
| EP3746426A4 (en) | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use | |
| IL313509A (en) | Reduction of proton tyrosine kinase (btk) by fusing btk inhibitors with an e3 ligase ligand and methods of use | |
| Lutwak et al. | Orlicz projection bodies | |
| MX2022012178A (es) | Compuestos, composiciones farmaceuticas y metodos para la preparacion de compuestos y para su uso. | |
| Humbert | Impression, sunset | |
| MX2015011733A (es) | Combinaciones de inhibidores de la tirosina quinasa de bruton e inhibidores de cyp3a4. | |
| EP4457230A4 (en) | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH AN E3 LIGASE LIGAND AND METHODS OF USE | |
| PH12016500575A1 (en) | Inhibitors of bruton`s tyrosine kinase | |
| GEP20186940B (en) | Administration d’un inhibiteur d’enzyme activant nedd8 et agent d’hypométhylation | |
| MX2021004568A (es) | Inhibidores de cinasa heterociclicos y usos de los mismos. | |
| MX2018010032A (es) | Formulaciones de antagonista de il-6 y sus usos. | |
| WO2019197605A3 (en) | Drug combinations for use in the treatment of ras-mutant cancer | |
| EP4051282A4 (en) | METHODS OF TREATING CANCER IN BIOMARKER-IDENTIFIED PATIENTS WITH CYCLIN-DEPENDENT KINASE 7 (CDK7) INHIBITORS | |
| PH12021551805A1 (en) | Treatment of skin lesions and pruritus in prurigo nodularis patients | |
| Guo | Major response to everolimus in melanoma with acquired imatinib resistance | |
| HK40082195A (en) | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use | |
| Milošević et al. | Quality of life in lung cancer patients due to treatment | |
| Hamby et al. | Life paths measurement packet | |
| Seo et al. | Exercise and cancer protection: from ‘prevention’to ‘therapeutics’? | |
| Hong et al. | 930TiP innovaTV 207: New dosing cohort in the open label phase II study of tisotumab vedotin in solid tumors | |
| Jo et al. | Comparison of single imputation methods in 2× 2 cross-over design with missing observations | |
| Wickrama et al. | Perceived Stress Scale--Revised | |
| Baumeister | Unsound interpretation of findings on a measurement bias in antidepressant drug research. | |
| Jouinot et al. | Biotherapies in metastatic colorectal cancers in 2014 |